Registry to optimize management and outcomes for patients with acute myocardial infarction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The OPTIMISER Registry aims to collect both baseline and clinical data from patients presenting with acute myocardial infarction (AMI) who are treated with percutaneous coronary intervention (PCI). This observational study will analyze procedural success and clinical outcomes, comparing results across different clinical subgroups. It will assess various procedural outcomes, long-term clinical outcomes, and the impact of different devices and strategies used during PCI. Additionally, the study will evaluate predictors for stent implantation failure and the effects of antithrombotic regimens on patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subject \>18 years of age
* Individuals who are newly diagnosed with AMI or have been diagnosed with AMI (STEMI or NSTEMI) within the last 5 years (since 2016).
* Subjects must be willing to sign a patient informed consent (PIC) OR a patient ́s relative/ proxy are willing to provide PIC or patients have signed the General Consent (GK).

Exclusion Criteria:

* Patient unwilling or unable to provide informed consent
* Patients with no ACS/AMI (e.g. Takotsubo cardiomyopathy, acute heart failure not related to AMI)

Where it's running

• Luzerner Heart Centre
  Lucerne, Switzerland Recruiting

Study contacts

• Principal investigator: Florim Cuculi, M.D. — Luzerner Kantonsspital
• Study coordinator: Florim Cuculi, M.D.
• Email: florim.cuculi@luks.ch
• Phone: +41412052134

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Breisgau PHENO-HEART MI: Understanding Heart Attack Biology in Adults

  This observational study in adults with STEMI or NSTEMI looks at the body’s immune response after a heart attack to understand how tissue damage and healing affect outcomes.

  Recruiting University Hospital Freiburg · Freiburg im Breisgau · NCT06166407

• Early single antiplatelet therapy after IVUS-guided PCI in ACS

  This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.

  Recruiting Phase 4 Gyeongsang National University Hospital · Jinju, Gyeongsangnam-do · NCT07684742

• Surgery to treat myocardial bridge in coronary arteries

  This study tests if a special heart surgery can help people with symptoms from a condition called myocardial bridge feel better and improve their quality of life.

  Recruiting Xi'an International Medical Center Hospital · Xi'an, Shaanxi · NCT06857838

• Using a smartphone device to record 12-lead ECGs for heart attack diagnosis

  This study is testing a smartphone device that records heart activity to see if it can help doctors quickly diagnose heart attacks in adults who come to the emergency room with chest pain.

  Recruiting at 2 sites AliveCor · Rochester, Minnesota and 3 other locations · NCT06271577

• Using Dapagliflozin to Prevent Heart Changes After a Heart Attack

  This study tests if the medication dapagliflozin can help prevent heart problems in people who have had a heart attack and have some heart weakness.

  Recruiting Phase 3 Assistance Publique - Hôpitaux de Paris · Paris · NCT05764057

• Registry collecting data on patients undergoing heart artery procedures

  This study is collecting information from patients who are having heart artery procedures to see how they do during and after their treatment.

  Recruiting Federico II University · Naples · NCT05248165

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.